BIOMAT Database Logo BIOMAT Database Logo

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. 2006

C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.

Autologous stem cell transplantation (ASCT) is an effective treatment strategy for mantle-cell lymphoma (MCL) demonstrating significantly prolonged progression-free survival (PFS) when compared to interferon-alpha maintenance therapy of patients in first remission. The study of absolute lymphocyte count at day 15 (ALC-15) after ASCT as a prognostic factor in non-Hodgkin lymphoma (NHL) included different lymphoma subtypes. The relationship of ALC-15 after ASCT in MCL has not been specifically addressed. We evaluated the impact of ALC-15 recovery on survival of MCL patients undergoing ASCT. We studied 42 consecutive MCL patients who underwent ASCT at the Mayo Clinic in Rochester from 1993 to 2005. ALC-15 threshold was set at 500 cells/microl. The median follow-up after ASCT was 25 months (range, 2-106 months). The median overall survival (OS) and PFS times were significantly better for the 24 patients who achieved an ALC-15 >or=500 cells/microl compared with 18 patients with ALC-15 <500 cells/microl (not reached vs 30 months, P<0.01 and not reached vs 16 months, P<0.0006, respectively). Multivariate analysis demonstrated ALC-15 to be an independent prognostic factor for OS and PFS. The ALC-15 >or=500 cells/microl is associated with a significantly improved clinical outcome following ASCT in MCL.

UI MeSH Term Description Entries
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014182 Transplantation, Autologous Transplantation of an individual's own tissue from one site to another site. Autografting,Autologous Transplantation,Autotransplantation,Autograftings,Autologous Transplantations,Autotransplantations,Transplantations, Autologous

Related Publications

C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.
July 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
August 2001, Blood,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
February 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma.
June 2006, Bone marrow transplantation,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
September 2017, The New England journal of medicine,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
January 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
October 2008, Bone marrow transplantation,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Double autologous stem cell transplantation in mantle cell lymphoma.
September 2002, Transplantation,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Autologous hematopoietic stem cell transplantation for mantle cell lymphoma.
January 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
C Joao, and L F Porrata, and D J Inwards, and S M Ansell, and I N Micallef, and P B Johnston, and D A Gastineau, and S N Markovic
Autologous stem cell transplantation in patients with mantle cell lymphoma.
June 2002, Leukemia & lymphoma,
Copied contents to your clipboard!